Month: November 2025

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by...

Synergy CHC Corp. (NASDAQ: SNYR) Adds Five New Direct Store Delivery Partners, Expanding FOCUSfactor Functional Beverage Distribution to Ten States Nationwide

WESTBROOK, Maine, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer...

error: Content is protected !!